A practical reference on obesity research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-27 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Sustainability == Sustainability has become a major policy objective in South Africa's logistics sector. Because road freight dominates the country's land freight system, most sustainability initiatives focus on reducing emissions from trucking, while increasing the use of rail. 2025 research on the Gauteng province's freight industry showed that many road freight companies are adopting green logistics practices, primarily through increased operational efficiency. Measures include route optimization, higher vehicle utilization and backhauling, lower-emission trucks, the use of alternative fuels, and the electrification of suitable fleets. South Africa's warehouses and logistics facilities are increasingly incorporating rooftop solar photovoltaic systems, battery storage systems, electric material-handling equipment, and energy-efficient refrigeration. Energy efficient warehousing is one of the fastest-growing sustainability measures in the South African logistics sector. Sustainable freight corridors continue to be developed in South Africa. A network of off-grid solar-powered charging infrastructure for heavy-duty electric trucks is being rolled out along major highways, by Cape Town-based company Charge. The EV charging network operator, founded in 2021, is installing 120 charging stations, designed specifically for electric trucks. The chargers are planned to be located along the N3 freight corridor between Johannesburg and Durban, with future expansion planned along the N1 corridor.
aid, though it was under the first five years of the Plan Colombia. In March 2015, it was revealed DEA agents were participating in drug cartel-funded sex parties with prostitutes. Agents were provided with expensive gifts, weapons, and money from drug cartel members. As a result, the head of the US Drug Enforcement Administration, Michele Leonhart, announced her retirement. According to the 2022 Truth Commission report, the 2019 arrest of Jesús Santrich on drug trafficking charges, which was a joint operation by the DEA and Colombian Attorney General Néstor Humberto Martínez, was intended to send a message from the Colombian Attorney General's to the Colombian public that the peace process had failed. Santrich's arrest led to hundreds of ex-guerrillas taking up arms again, which jeopardized the peace process.
African Americans had roughly three times the level of Lp(a); however, Lp(a) also predicted an increased risk of stroke. Approximate levels of risk are indicated by the results below, although at present, there are various methods by which to measure Lp(a). A standardized international reference material has been developed and is accepted by the WHO Expert Committee on Biological Standardization and the International Federation of Clinical Chemistry and Laboratory Medicine. Although further standardization is still needed, the development of a reference material is an important step toward standardizing results. Lipoprotein(a) — Lp(a)
This differs from a case of constant extraction field where the ions are accelerated instantaneously upon being formed. Delayed extraction is used with MALDI or laser desorption/ionization (LDI) ion sources where the ions to be analyzed are produced in an expanding plume moving from the sample plate with a high speed (400–1000 m/s). Since the thickness of the ion packets arriving at the detector is important to mass resolution, on first inspection it can appear counter-intuitive to allow the ion plume to further expand before extraction. Delayed extraction is more of a compensation for the initial momentum of the ions: it provides the same arrival times at the detector for ions with the same mass-to-charge ratios but with different initial velocities. In delayed extraction of ions produced in vacuum, the ions that have lower momentum in the direction of extraction start to be accelerated at higher potential due to being further from the extraction plate when the extraction field is turned on. Conversely, those ions with greater forward momentum start to be accelerated at lower potential since they are closer to the extraction plate. At the exit from the acceleration region, the slower ions at the back of the plume will be accelerated to greater velocity than the initially faster ions at the front of the plume. So after delayed extraction, a group of ions that leaves the ion source earlier has lower velocity in the direction of the acceleration compared to some other group of ions that leaves the ion source later but with greater velocity.
=== Osteoporosis === In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events.
Sources: en.wikipedia.org
== State-affiliated media label controversy == On April 5, 2023, the Twitter account for National Public Radio (NPR) received a label that it was "state-affiliated", despite the fact it receives less than 1% of its funding from the government; Voice of America (VOA), a state-affiliated media arm of the United States, did not receive a label. NPR CEO John Lansing condemned Twitter for the labeling. A similar label was added to Public Broadcasting Station's (PBS) Twitter account on April 8. According to PBS, the broadcaster has no intention to use its Twitter account after receiving the label. NPR announced it had quit Twitter on April 12 after the label was changed to "government-affiliated". The decision was a reversal of the company's previous treatment towards NPR, which it cited as an example of a public news organization that is not state-affiliated. The British Broadcasting Corporation (BBC) also received a government-affiliated label, but appealed to Musk. The Canadian Broadcasting Corporation (CBC) received a label stating it was "69% government-funded", in apparent reference to the sex position, after Conservative Party of Canada leader Pierre Poilievre told Musk to apply the label. The CBC is 66% government-funded, and stopped tweeting after the incident. On April 22, Twitter dropped the state-affiliated and government-affiliated labels entirely, including for Russia's RT and China's Xinhua News and China Global Television Network (CGTN). According to Musk, the idea to drop the labels came from author Walter Isaacson.
In 1964, the first franchise was purchased by former police officer Kermit Bekke. This location, located at 1654 West Carson Street in Torrance, California, had its grand opening on May 28, 1965. Bekke sold his franchise a year and a half later. This location closed in 1975 when it moved across the street to store #1130 at 1619 West Carson Street, which itself would close in the late 1990s and subsequently be repurposed. On January 20, 1967, the 100th Taco Bell grand opening took place in Anaheim, located at 400 South Brookhurst (store #63); this location would later be replaced by a new location at 324 South Brookhurst in 1993. The first Taco Bell restaurant east of the Mississippi River (the 270th to open, store #258) opened at 2050 East Main Street in Springfield, Ohio, on September 20, 1968. Original Taco Bells featured only walk-up window service without indoor seating or drive-thru service. Inside seating was added sporadically in 1968 and drive-thru service was not generally available until 1980. As of 2025, seven original mission-style operating Taco Bell restaurants still remain, located in California and Colorado. A mission-style location (opened in April 1976) that operated in Honolulu, Hawaii (store #1281) remodeled in 2024, and another Mission-style location in Scottsdale, Arizona (store #31, opened circa July 3, 1966) closed on April 12, 2025.
In many species—including all vertebrates—the nervous system is the most complex organ system in the body, with most of the complexity residing in the brain. The human brain alone contains around one hundred billion neurons and one hundred trillion synapses; it consists of thousands of distinguishable substructures, connected to each other in synaptic networks whose intricacies have only begun to be unraveled. At least one out of three of the approximately 20,000 genes belonging to the human genome is expressed mainly in the brain. Due to the high degree of plasticity of the human brain, the structure of its synapses and their resulting functions change throughout life. Making sense of the nervous system's dynamic complexity is a formidable research challenge. Ultimately, neuroscientists would like to understand every aspect of the nervous system, including how it works, how it develops, how it malfunctions, and how it can be altered or repaired. Analysis of the nervous system is therefore performed at multiple levels, ranging from the molecular and cellular levels to the systems and cognitive levels. The specific topics that form the main focus of research change over time, driven by an ever-expanding base of knowledge and the availability of increasingly sophisticated technical methods. Improvements in technology have been the primary drivers of progress. Developments in electron microscopy, computer science, electronics, functional neuroimaging, and genetics and genomics have all been major drivers of progress.
== Release == Portal was first released as part of The Orange Box for Windows and Xbox 360 on October 10, 2007, and for the PlayStation 3 on December 11, 2007. In addition to Portal, The Orange Box includes Half-Life 2 and its two add-on episodes, as well as Team Fortress 2. Portal's inclusion within The Orange Box was considered an experiment by Valve; having no idea of the success of Portal, the bundle provided it a "safety net" via means of these other games. Portal was kept to a modest length in case the game did not go over well with players. The game was released as a standalone retail product on April 9, 2008, with the Windows version also available as a download through Steam. In January 2008, Valve released a special demo titled Portal: The First Slice, free to any Steam user using Nvidia graphics hardware, as part of a collaboration between the two companies. The demo comes packaged with Half-Life 2: Deathmatch, Peggle Extreme, and Half-Life 2: Lost Coast. The demo includes test chambers 00 to 10 (eleven in total). Valve has since made the demo available to all Steam users. Portal is the first Valve-developed game to be added to the OS X-compatible list of games available on the launch of the Steam client for Mac on May 12, 2010, supporting Steam Play, in which buying the game on Macintosh or Windows computer makes it playable on both. As part of the promotion, Portal was offered as a free game for any Steam user during the two weeks following the Mac client's launch. Within the first week of this offer, over 1.5 million copies were downloaded through Steam.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.